[{"indications": "Indications\u00a0acute hypotension (see notes above); priapism\r\n(%s\n(From 7.4.5 Drugs for erectile dysfunction: British National Formulary)\n7.4.5 Drugs for erectile dysfunction) [unlicensed\r\nindication]", "name": "PHENYLEPHRINE HYDROCHLORIDE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "2 Cardiovascular system", "2.7 Sympathomimetics", "2.7.2 Vasoconstrictor sympathomimetics", "PHENYLEPHRINE HYDROCHLORIDE"], "cautions": "Cautions\u00a0see under Noradrenaline; longer duration of action than noradrenaline (norepinephrine), see below; coronary diseaseHypertensive response\u00a0Phenylephrine\r\nhas a longer duration of action than noradrenaline, and an excessive\r\nvasopressor response may cause a prolonged rise in blood pressure", "side-effects": "Side-effects\u00a0see under Noradrenaline; also tachycardia or reflex\r\nbradycardia", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/2759.htm", "doses": ["By subcutaneous or intramuscular injection, 2\u20135\u00a0mg, followed if necessary\r\nafter at least 15 minutes by further doses of 1\u201310\u00a0mg", "By slow intravenous injection of\r\na 1\u00a0mg/mL solution, 100\u2013500\u00a0micrograms repeated as necessary after\r\nat least 15 minutes", "By intravenous infusion, initial\r\nrate up to 180\u00a0micrograms/minute reduced to 30\u201360\u00a0micrograms/minute\r\naccording to response"], "pregnancy": "Pregnancy\u00a0avoid if possible; malformations reported following\r\nuse in first trimester; fetal hypoxia and bradycardia reported in\r\nlate pregnancy and labour"}, {"indications": "Indications\u00a0mydriasis; see also notes above", "name": "PHENYLEPHRINE HYDROCHLORIDE With tropicamide", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "11 Eye", "11.5 Mydriatics and cycloplegics", "Sympathomimetics", "PHENYLEPHRINE HYDROCHLORIDE", "With tropicamide"], "cautions": "Cautions\u00a0children and elderly (avoid 10% strength); cardiovascular\r\ndisease (avoid or use 2.5% strength only); corneal epithelial damage; ocular hyperaemia; susceptibility to angle-closure glaucoma; tachycardia; hyperthyroidism; diabetes; cerebral arteriosclerosis; asthma; prostate disorders; see also notes above", "side-effects": "Side-effects\u00a0\n(From 11.5 Mydriatics and cycloplegics: British National Formulary)\n11.5 Mydriatics and cycloplegics; also eye pain and stinging; blurred\r\nvision, photophobia; systemic effects include palpitations, tachycardia,\r\narrhythmias, hypertension, coronary artery spasm; very rarely dry mouth, tremor, headache, angle-closure glaucoma", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/218824.htm", "doses": ["Name[Mydriasert\u00ae (Spectrum Thea) ] Ophthalmic insert, phenylephrine\r\nhydrochloride 5.4\u00a0mg, tropicamide 280\u00a0micrograms, net price 1\u00a0unit\r\n= \u00a34.20Dose\u00a0for pre-operative mydriasis, or for diagnostic procedures\r\nwhen monotherapy insufficient, adult over 18 years, apply 1\u00a0insert into the lower conjunctival sac up\r\nto max. 2 hours before procedure; remove insert within 30 minutes\r\nof satisfactory mydriasis, and within 2 hours of applicationNote\u00a0Patients with severe dry eyes may require\r\na drop of saline to improve insert tolerance"]}]